natgillin/translations-raw huggingface dataset:
Ebixa 5 mg film-coated tablets Ebixa 10 mg film-coated tablets Ebixa 15 mg film-coated tablets Ebixa 20 mg film-coated tablets Memantine hydrochloride
Ebixa 5 mg filmom obložene tablete Ebixa 10 mg filmom obložene tablete Ebixa 15 mg filmom obložene tablete Ebixa 20 mg filmom obložene tablete memantinklorid
Ebixa 5 mg/pump actuation oral solution memantine hydrochloride
Ebixa 5 mg/oralna otopina s pokretanjem pomoću pumpice memantinklorid
Ebixa belongs to a group of medicines called NMDA- receptor antagonists.
Ebixa spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
Ebixa contains the active substance memantine hydrochloride.
Ebixa sadrži djelatnu tvor memantinklorid.
Ebixa film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Ebixa filmom obložene tablete su blijedocrvene do sivo-crvene, ovalno duguljaste filmom obložene tablete s utisnutom oznakom ‘20’ na jednoj strani i ‘MEM’ na drugoj strani.
Ebixa is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Ebixa se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
EBMT criteria g All randomised patients with secretory disease
EBMT kriteriji g Svi randomizirani bolesnici sa sekrecijskom bolešću
eborrhoeic dermatitis,
heilitis
EBR with GZR + RBV
EBR s GZR-om + RBV
EBR with GZR 12 Weeks N=519
EBR s GZR-om 12 tjedana N=519
EBR with GZR 12 Weeks N=65
EBR s GZR-om 12 tjedana N=65
EBR with GZR for 12 weeks (N = 312)
EBR s GZR-om tijekom 12 tjedana (N = 312)
EBR/GZR for 12 weeks (DTG).
EBR/GZR* tijekom 12 tjedana (N=316)
EBR/GZR for 12 weeks (N=201)
EBR/GZR tijekom 12 tjedana (N=201)
EBV (Epstein-Barr virus) lymphoproliferative disease
EBV (Epstein-Barrov virus) limfoproliferativna bolest
EBV associated lymphoproliferative disorder**,lung cancer, rectal cancer, breast cancer, sarcoma, kaposi's sarcoma, prostate cancer, cervix carcinoma, laryngeal cancer, lymphoma, multiple myeloma, transitional cell carcinoma
limfoproliferativna bolest povezana s EBV**, karcinom pluća, karcinom rektuma, karcinom dojke, sarkom, Kaposijev sarkom, karcinom prostate, karcinom grlića maternice, karcinom larinksa, limfom, multipli mijelom, karcinom prijelaznih stanica
EBV seronegative patients receiving immunosuppressants are at a particularly increased risk for PTLD.
Bolesnici seronegativni na EBV koji su primali imunosupresive imali su osobito povišen rizik od PTLD-a.
EBV-Viral Capsid Antigen (VCA)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders.
U bolesnika s negativnim nalazom EBV virusnog kapsidnog antigena (VCA) zabilježen je povećani rizik od razvoja limfoproliferativnih poremećaja.
EBV-Viral Capsid Antigen (VCA)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders.
Zabilježeno je da bolesnici s negativnim nalazom EBV- virusnog kapsidnog antigena (VCA) imaju povećan rizik od razvoja limfoproliferativnih poremećaja.
Ebymect 5 mg/1,000 mg are 10.5 x 21.5 mm oval, yellow film-coated tablets.
Ebymect 5 mg/1000 mg su ovalne, žute, filmom obložene tablete veličine 10,5 x 21,5 mm.
Ebymect 5 mg/850 mg are 9.5 x 20 mm oval, brown film-coated tablets.
Ebymect 5 mg/850 mg su ovalne, smeđe, filmom obložene tablete veličine 9,5 x 20 mm.
Ebymect can also be used to replace dapagliflozin and metformin taken as separate tablets.
Ebymect se može također koristiti kao zamjena za dapagliflozin i metformin koji se uzimaju kao zasebne tablete.
Ebymect contains two different active substances, which work in different ways:
Ebymect sadrži dvije različite djelatne tvari koje djeluju različito:
Ebymect is a diabetes medicine that contains the active substances dapagliflozin and metformin.
Ebymect je lijek koji sadrži djelatne tvari dapagliflozin i metformin.
Ebymect is available as tablets (5 mg dapagliflozin/850 mg metformin and 5 mg dapagliflozin/ 1,000 mg metformin) and can only be obtained with a prescription.
Ebymect je dostupan kao tablete (5 mg dapagliflozina/850 mg metformina i 5 mg dapagliflozina/1 000 mg metformina) i izdaje se samo na liječnički recept.
Ebymect must not be used in:
Ebymect se ne smije koristiti u:
ECALTA 100 mg powder for concentrate for solution for infusion Anidulafungin
ECALTA 100 mg prašak za koncentrat za otopinu za infuziju anidulafungin
ECALTA should be given to you once a day, by slow infusion (a drip) into your vein.
ECALTA Vam se treba davati jedanput na dan, sporom infuzijom (drip) u venu.
ECALTA will always be prepared and given to you by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only).
Lijek ECALTA će Vam uvijek pripremiti i primijeniti liječnik ili zdravstveni djelatnik (više informacija o načinu pripreme nalazi se na kraju ove upute u dijelu namijenjenom samo liječnicima i zdravstvenim djelatnicima).
Ecansya 150 mg film-coated tablets (tablets) are light peach coloured, oblong shaped, biconvex tablets of 11.4 mm in length and 5.3 mm in width, debossed with "150" on one side and plain on other side.
Ecansya 150 mg filmom obložene tablete (tablete) su svijetle boje breskve, duguljaste, bikonveksne tablete 11,4 mm dužine i 5,3 mm širine, s oznakom „150“ na jednoj strani i obične na drugoj strani.
Ecansya 150 mg film-coated tablets Capecitabine
Ecansya 150 mg filmom obložene tablete kapecitabin
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets
Ecansya 150 mg filmom obložene tablete Ecansya 300 mg filmom obložene tablete Ecansya 500 mg filmom obložene tablete
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 150 mg filmom obložene tablete Ecansya 300 mg filmom obložene tablete Ecansya 500 mg filmom obložene tablete kapecitabin
Ecansya 150 mg tablets Capecitabine
Ecansya 150 mg tablete kapecitabin
Ecansya 300 mg film-coated tablets Capecitabine
Ecansya 300 mg filmom obložene tablete kapecitabin
Ecansya 300 mg tablets Capecitabine
Ecansya 300 mg tablete kapecitabin
Ecansya 500 mg film-coated tablets are peach colored, oblong shaped, biconvex tablets of 15.9 mm in length and 8.4 mm in width, debossed with "500" on one side and plain on other side.
Ecansya 500 mg filmom obložene tablete su boje breskve, duguljaste, bikonveksne tablete 15,9 mm dužine i 8,4 mm širine, s oznakom „500“ na jednoj strani i obične na drugoj strani.
Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 500 mg filmom obložene tablete kapecitabin
Ecansya 500 mg tablets Capecitabine
Ecansya 500 mg tablete kapecitabin
Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Ecansya može potaknuti razvoj teških kožnih reakcija poput Stevens-Johnsonova sindroma i toksične epidermalne nekrolize.
Ecansya is indicated for the treatment of: for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1).
Ecansya je indicirana za liječenje: adjuvantno liječenje bolesnika nakon operacije karcinoma kolona stadija III (stadij C prema Dukesovoj klasifikaciji) (vidjeti dio 5.1).
Ecansya is not indicated in children and adolescents.
Ecansya nije namijenjena za primjenu u djece i adolescenata.
Ecansya should only be prescribed by a qualified physician experienced in the utilisation of anti- neoplastic medicinal products.
Lijek Ecansya može propisati samo liječnik specijalist s iskustvom u primjeni antineoplastičnih lijekova.
Ecansya tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken).
Ecansya tablete se preporučuje uzimati 14 dana, nakon čega slijedi 7 dana pauze (bez uzimanja tableta).
Ecansya tablets should be swallowed with water within 30 minutes after a meal.
Ecansya tablete moraju se progutati s vodom unutar 30 minuta nakon obroka.
Ecansya with food and drink
Ecansya s hranom i pićem
Ecchymosis
bol u prsnom košu
Ecchymosis
Ehimoza
ecchymosis
kolelitijaza
Ecchymosis
niženi bikarbonati
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin)
ekhimoza (mala modrica koju uzrokuje istjecanje krvi iz oštećenih krvnih žila u koži)
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin).
ekhimoza (mala modrica koju uzrokuje istjecanje krvi iz oštećenih krvnih žila u koži)
ecchymosis (large skin hematoma)
ekhimoza (veliki hematom na koži)
Ecchymosis (Petechiae, Purpura)
ekhimoza (petehije, purpura)
Ecchymosis or Swelling‡ at the injection site, injection-site rash‡
ekhimoze ili oticanje‡ na mjestu injiciranja, osip na mjestu injiciranja
Ecchymosis*
Ekhimoza
Ecchymosis***
ekhimoza
ecchymosis, pruritus
ekhimoza, pruritus
Ecchymosis, rash, urticaria
ekhimoza, osip, urtikarija
Ecchymosis, Skin haemorrhage
ekhimoza, kožno krvarenje
ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/m2 kao bolus 1. dan, svaka 3 tjedna), cisplatin (60 mg/m2 kao dvosatna infuzija 1. dan, svaka 3 tjedna) i 5-FU (200 mg/m2 dnevno u obliku kontinuirane infuzije putem centralnog venskog katetera)
ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/m2 kao bolus 1. dan, svaka 3 tjedna), cisplatin (60 mg/m2 kao dvosatna infuzija 1. dan, svaka 3 tjedna) i 5-FU (200 mg/m2 dnevno u obliku kontinuirane infuzije putem centralnog venskog katetera).
ECF: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/m2 kao bolus 1. dan, svaka 3 tjedna), cisplatin (60 mg/m2 kao dvosatna infuzija 1. dan, svaka 3 tjedna) i 5-FU (200 mg/m2 dnevno u obliku kontinuirane infuzije putem centralnog venskog katetera)
ECG and Electrolyte Monitoring Recommendations: Prior to initiating therapy with TRISENOX, a 12-lead ECG must be performed and serum electrolytes (potassium, calcium, and magnesium) and creatinine must be assessed; preexisting electrolyte abnormalities must be corrected and, if possible, medicinal products that are known to prolong the QT interval must be discontinued.
Preporuke za praćenje EKG-a i nadzor nad elektrolitima: Prije početka liječenja TRISENOXOM mora se snimiti 12-kanalni EKG i odrediti elektrolite u serumu (kalij, kalcij i magnezij) te kreatinin; postojeće abnormalnosti u elektrolitima moraju se korigirati i, ako je moguće, prekinuti primjenu lijekova za koje se zna da produljuju QT interval.
ECG monitoring should be performed in high-risk patients as clinically indicated.
Kod visoko rizičnih pacijenata potrebno je EKG praćenje kao što je klinički indicirano.
ECG or echocardiography) for evidence of cardiovascular effects that may require further cardiovascular examination and investigation.
EKG ili ehokardiografija) zbog dokaza o kardiovaskularnim učincima koji mogu zahtijevati daljnje kardiovaskularne preglede i pretrage.
ECG QT interval prolongation
Produljenje QT intervala u EKG-u
ECG QTc interval prolonged
produljenje QTc intervala na EKG-u
ECG) and/or laboratory monitoring is recommended for patients receiving concomitant digoxin and vandetanib, and such patients may require a lower dose of digoxin. (For vandetanib monitoring, see section 4.2 Posology and method of administration and section 4.4 Special warnings and special precautions).
EKG) i/ili laboratorijsko praćenje za bolesnike koji istodobno primaju digoksin i vandetanib, te će takvim bolesnicima možda biti potrebno smanjiti dozu digoksina. (Za praćenje vandetaniba, molimo pogledajte dio 4.2 Doziranje i način primjene i dio 4.4 Posebna upozorenja i mjere opreza pri uporabi.)
Echinococcosis represents a hazard for humans, and is a notifiable disease to the World Organisation for Animal Health (OIE).
Kako ehinokokoza predstavlja opasnost za ljude potrebno ju je prijaviti Svjetskoj organizaciji za zdravlje životinja (OIE).
Echinococcus multilocularis (adult)
Echinococcus multilocularis (adulti)
Echinococcus multilocularis (adult) Lungworms
Echinococcus multilocularis (adulti)
Echo- cardiogram abnormal
Vrlo često
Echocardiogram is recommended before initiation of INCRELEX treatment in all patients.
Kod svih bolesnika preporučuje se ultrazvuk srca prije započinjanja liječenja INCRELEXOM.
Eckert & Ziegler EURO-PET Berlin GmbH - BERLIN Max-Planck-Strasse 4
Eckert & Ziegler EURO-PET Berlin GmbH – BERLIN Max-Planck-Strasse 4
Eckert & Ziegler EURO-PET Berlin GmbH, Germany
Eckert & Ziegler EURO-PET Berlin GmbH, Njemačka
Eckert & Ziegler EURO-PET Koeln/Bonn GmbH, Germany
Eckert & Ziegler EURO-PET Koeln/Bonn GmbH, Njemačka
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o. - WARSAW ul.
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o. – WARSAW ul.
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o., Poland
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o., Poljska
Eckert & Ziegler Radiopharma GmbH Branch Braunschweig
Eckert & Ziegler Radiopharma GmbH Podružnica Braunschweig
Eclampsia and severe pre-eclampsia requiring delivery
Eklampsija i teška preeklampsija koja zahtijeva porod
ECOG performance scores were 0 for 61% of patients and 1 for 39% of patients.
61% bolesnika imalo je funkcionalni ECOG status 0, a njih 39% funkcionalni ECOG status 1.
ECOG Performance Status, n (%)
ECOG funkcionalni status, n (%)
ECOG Performance Status, n (%) 0
ECOG status izvedbe, n (%) 0
ECOG PS=0
ECOG PS = 0
ECOG PS=1
ECOG PS = 1
ECOG=0 or 1
ECOG=0 ili 1
Econor 10% 2 g/kg feed
Econor 10 % 2 g/kg hrane
Econor 10% Hypromellose Talc
Econor 10 % Hipromeloza Talk
Econor 10% mg Econor 10% premix/kg feed = Dosage required (mg/kg) x 10 x bodyweight (kg)/Daily feed intake (kg).
Econor 10 % mg Econor 10 % premiks/kg hrane = potrebna doza (mg/kg) x 10 x tjelesna masa (kg)/dnevnog unosa hrane (kg)
Econor 10% oral powder for pigs
Econor 10 % oralni prašak za svinje
Econor 10% oral powder for pigs is available in 1 kg bags.
Econor 10 % oralni prašak za svinje dostupan je u vrećama od 1 kg.
Econor 10% oral powder for pigs Valnemulin
Econor 10 % oralni prašak za svinje Valnemulin
Econor 10% oral powder for pigs Valnemulin hydrochloride
Econor 10 % oralni prašak za svinje Valnemulin hidroklorid
Econor 10% oralpowder (g)
Econor 10 % oralni prašak (g)
Econor 10% premix and Econor 10% oral powder
Econor 10 % premiks i Econor 10 % oralni prašak
Econor 10% premix contains valnemulin in the form of valnemulin hydrochloride.
Econor 10 % premiks sadrži valnemulin u obliku valnemulin hidroklorida.
Econor 10% premix for medicated feed for pigs and rabbits
Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće
Econor 10% premix for medicated feed for pigs and rabbits is available in 1 kg and 25 kg bags.
Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće dostupan je u vrećama od 1 kg i 25 kg.
Econor 10% premix for medicated feed for pigs and rabbits Valnemulin
Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće Valnemulin
Econor 10% premix for medicated feed for pigs and rabbits Valnemulin hydrochloride
Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće Valnemulin hidroklorid
Econor 10%, Econor 50%:
Econor10 %, Econor 50 %:
Econor 50% 50 mg/kg feed
Econor 50 % 50 mg/kg hrane
Econor 50% Hypromellose Talc.
Econor 50 % Hipromeloza Talk
Econor 50% mg Econor 50% premix/kg feed = Dosage required (mg/kg) x 2 x bodyweight (kg)/Daily feed intake (kg).
Econor 50 % mg Econor 50 % premiks/kg hrane = potrebna doza (mg/kg) x 2 x tjelesna masa (kg)/dnevnog unosa hrane (kg)
Econor 50% premix contains valnemulin in the form of valnemulin hydrochloride.
Econor 50 % premiks sadrži valnemulin u obliku valnemulin hidroklorida.
Econor 50% premix for medicated feed for pigs
Econor 50 % premiks za izradu ljekovite hrane za svinje
Econor 50% premix for medicated feed for pigs Valnemulin
Econor 50 % premiks za izradu ljekovite hrane za svinje Valnemulin
Econor 50% premix for medicated feed for pigs Valnemulin hydrochloride
Econor 50 % premiks za izradu ljekovite hrane za svinje Valnemulin hidroklorid
Econor 50% premix Sandoz GmbH Biochemiestrasse 10
Econor 50 % premiks Sandoz GmbH Biochemiestrasse 10
Econor at a dose of 1-1.5 mg valnemulin/kg bodyweight/day (i.e.
Econor pri dozi od 1-1,5 mg valnemulin/kg tjelesne težine/danu (tj.
Econor contains valnemulin in the form of valnemulin hydrochloride.
Econor sadrži valnemulin u obliku valnemulin hidroklorida.
Econor is a medicine that contains the active substance valnemulin.
Econor je lijek koji sadrži djelatnu tvar valnemulin.
Econor premix is mixed into pig or rabbit food by an authorised feed mill and the resulting “medicated feeding stuff” is then distributed to the farmer to treat a large number of pigs or rabbits.
Predmješavina Econor miješa se s hranom za svinje ili zečeve od strane ovlaštenog mlina, a dobivena „ljekovita hrana” potom se distribuira farmeru za liječenje velikog broja svinja ili zečeva.
Econor was used either to treat animals that were already affected by a disease or to prevent the outbreak of the disease in pigs in contact with diseased animals as well as on farms with a history of repeatedly re-occurring disease.
Econor je korišten ili za liječenje životinja koje su već zahvaćene bolešću ili za sprječavanje izbijanja bolesti kod svinja koje su u kontaktu s bolesnim životinjama kao i na farmama gdje je bolest opetovano izbijala u prošlosti.
ECOPORC SHIGA suspension for injection for pigs
ECOPORC SHIGA suspenzija za injekcije za svinje
ECT [x-fold upper limit of normal]
ECT [x puta od gornje granice normale]
ection 4.3)
dio 4.3).
ection 4.3).
4.3).
ection 4.3).
dio 4.3).
ection 4.4)
(vidjeti dio 4.4)
ection 4.4)
dio 4.4)
ection 4.4)
Dizartrija
ection 4.4)*****
u krvi (vidjeti dio 4.4)
ection 4.4),
dio 4.4), aplastična
ection 4.4), aplastic
(vidjeti dio 4.4.),
ection 4.4).
interakcija lijeka.
Ectoparasites
Ektoparaziti
Ectopic pregnancy
Izvanmaternična trudnoća
Eculizumab binds to and inhibits a specific protein in the body that causes inflammation and so prevents your body’s systems from attacking and destroying vulnerable blood cells.
Ekulizumab se veže za određene proteine u tijelu koji uzrokuju upalu i inhibira ih te tako sprječava sustave Vašeg tijela da napadaju i uništavaju osjetljive krvne stanice.
Eculizumab can block the body’s inflammatory response, and its ability to attack and destroy its own vulnerable blood and kidney cells.
Ekulizumab može blokirati upalni odgovor organizma i njegovu sposobnost da napada i uništava vlastite osjetljive stanice krvi i bubrega.
Eculizumab can block the body’s inflammatory response, and its ability to attack and destroy its own vulnerable PNH blood cells.
Ekulizumab može blokirati upalni odgovor organizma i njegovu sposobnost da napada i uništava vlastite osjetljive PNH krvne stanice.
Eculizumab has been designed to attach to the C5 complement protein, which is a part of the body’s defence system called the ‘complement system’.
Ekulizumab je dizajniran za vezivanje na komplementski protein C5, koji je dio obrambenog sustava tijela naziva „komplementski sustav”.
Eculizumab is a humanised monoclonal (IgG2/4κ) antibody produced in NS0 cell line by recombinant DNA technology.
Ekulizumab je humanizirano monoklonsko protutijelo IgG2/4κ proizvedeno na staničnoj liniji NS0 tehnologijom rekombinantne DNK.
Eculizumab is a humanised monoclonal IgG2/4 k antibody produced in NS0 cell line by recombinant DNA technology.
Ekulizumab je humanizirano monoklonsko IgG2/4 k protutijelo proizvedeno na staničnoj liniji NS0 tehnologijom rekombinantne DNK.
eculizumab rate,
P<0,0001
Eculizumab should be given to a pregnant woman only if clearly needed.
Ekulizumab se smije davati tijekom trudnoće samo ako je neophodan.
Eculizumab, the active ingredient in Soliris, is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.
Ekulizumab, djelatna tvar u lijeku Soliris, inhibitor je terminalne komponente komplementa koji se visokim afinitetom specifično veže za proteinsku C5 komponentu komplementa i tako inhibira njezino cijepanje na C5a i C5b te sprječava stvaranje kompleksa terminalnih komponenti komplementa C5b-9.
ECX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily continuously).
ECX: epirubicin (50 mg/m2 kao bolus 1. dan, svaka 3 tjedna), cisplatin (60 mg/m2 kao dvosatna infuzija 1. dan, svaka 3 tjedna) i kapecitabin (625 mg/m2 dvaput dnevno bez pauze)
ECX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily continuously).
ECX: epirubicin (50 mg/m2 kao bolus 1. dan, svaka 3 tjedna), cisplatin (60 mg/m2 kao dvosatna infuzija 1. dan, svaka 3 tjedna) i kapecitabin (625 mg/m2 dvaput dnevno bez pauze).
Eczema
Ekcem
eczema (itchy red patches on the skin)
ekcem (crvene mrlje po koži koje svrbe)
Eczema Alopecia Pruritus
Ekcem Alopecija Pruritus
Eczema Blister Erythema
mjehurići eritem
Eczema Erythema Exfoliative rash
Ekcem Eritem
Eczema nummular
Numularni ekcem
Eczema, Dermatitis, Rash, Urticaria
ekcem, dermatitis,
Eczema, Dermatitis, Rash, Urticaria
ekcem, dermatitis, osip,
Eczema, Dermatitis, Rash, Urticaria
ekcem, dermatitis, osip, urtikarija
eczema, dry skin, rash, itching,
ekcem, suha koža, osip, svrbež,
Eczema, erythema, hand dermatitis, psoriasis, rash generalised, rash pruritic, nail disorder
ekcem, eritem, dermatitis šake, psorijaza, generalizirani osip, osip sa svrbežom, promjene na noktima
eczema, erythema, rash
ekcem, eritem, osip
Eczema, redness of the skin
ekcem, crvenilo kože
eczema, swelling face, exfoliative rash
ekcem, oticanje lica, eksfolijativni osip
Eczema.
ekcem;
Eczema†
Ekcem
Edarbi 20 mg tablets Edarbi 40 mg tablets Edarbi 80 mg tablets
Edarbi 20 mg tablete Edarbi 40 mg tablete Edarbi 80 mg tablete
Edarbi 20 mg tablets Edarbi 40 mg tablets Edarbi 80 mg tablets Azilsartan medoxomil
Edarbi 20 mg tablete Edarbi 40 mg tablete Edarbi 80 mg tablete azilsartanmedoksomil
edation
umirenje (sedacija)
edation/somnolence, dystoniab, dizziness, dyskinesiab, tremor
akatizijab, sedacija/somnolencij a, distonijab, omaglica, diskinezijab, tremor
edative agents (e.g. midazolam administered by injection) buprenorphine (used to treat opioid addiction and pain).
edative (npr. midazolam primijenjen injekcijom) buprenorfin (primijenjuje se za liječenje ovisnosti o opijatima i boli)
edative agents (e.g. midazolam administered by injection) buprenorphine (used to treat opioid addiction and pain).
edative (npr. midazolam primijenjen injekcijom) buprenorfin (primjenjuje se za liječenje ovisnosti o opijatima i boli)
edative agents - such as midazolam administered by injection
lijekove za smirenje, poput midazolama primijenjena injekcijom
edative agents - such as midazolam administered by injection
lijekove za smirenje, poput midazolama primijenjenog injekcijom
edatives (e.g. midazolam administered by injection);
edativi (npr. midazolam primijenjen putem injekcije);
edatives (e.g. midazolam administered by injection); steroids (e.g. budesonide, dexamethasone, fluticasone propionate, ethinyl oestradiol).
edativi (npr. midazolam primijenjen putem injekcije); steroidi (npr. budezonid, deksametazon, flutikazon propionat, etinil estradiol).
edatives (e.g. midazolam administered by injection); steroids (e.g. budesonide, dexamethasone, fluticasone propionate, ethinyl oestradiol).
edativi (npr. midazolam primjenjen putem injekcije); steroidi (npr. budezonid, deksametazon, flutikazon propionat, etinil estradiol).
edatives and hypnotics, used to treat anxiety:
edative i hipnotike, primjenjuju se za liječenje tjeskobe: